CompletedPhase 2

Ozurdex for Combined Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema After Cataract Surgery

United States6 participantsStarted 2011-01

Plain-language summary

The purpose of the study is to determine where a sustained steroid delivery system (Ozurdex,Allergan) is safe and effective to treat Cystoid Macular Edema in diabetic patients after Cataract Surgery

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * DIABETIC PATIENTS WHO DEVELOP CYSTOID MACULA EDEMA AFTER CATARACT SURGERY (WITHIN 4-10 WEEKS AFTER SURGERY * VISUAL ACUITY WORSE THAN 20/32 Exclusion Criteria: * VISUAL ACUITY WORSE THAN 20/200 * MODERATE OR SEVERE GLAUCOMA (AS DEFINED AS USING \>2 TOPICAL GLAUCOMA MEDIATIONS. * USE OF SYSTEMIC, PERIOCULAR OR INTRAOCULAR CORTICOSTEROIDS WITHIN 30 DAYS OF ENROLLMENT

What they're measuring

BEST CORRECTED VISUAL ACUITY (ETDRS)

Timeframe: AT DAY 180

Trial details

NCT IDNCT01284478

SponsorNorthern California Retina Vitreous Associates

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2012-10

View on ClinicalTrials.gov More Pseudophakic Cystoid Macular Edema, trials